RxDoctor Payments Data

Grant Cagle, MD

Pulmonary Disease · Jonesboro, ARNPI 1053802306

Payments from drug & device makers

What this record shows

This record is dominated by education: $4,000 of the $5,839 with a category attached, or 68.5%. Intuitive Surgical accounts for 89.9% of it on its own, with 7 other manufacturers making up the rest.

$5,839in general payments, 2019–2025

Across 39 payments — averaging $149.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • GSK$209
  • Sanofi$107
  • Regeneron Healthcare Solutions, Inc.$99
  • AstraZeneca$67
  • Insmed, Inc.$58
  • plus $50 from 2 others

What the payments were for

  • Travel & lodging$1,23321%
  • Food & beverage$60610%
  • Education$4,00069%

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,839 in reported general payments places this provider in the 65th percentile of 102 pulmonary disease providers in Arkansas.

See all pulmonary disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$39,232
Medicare patients
228
Services billed
428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$18,663
Stiolto RespimatTiotropium Br/Olodaterol Hcl25$12,011
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$9,153
SymbicortBudesonide/Formoterol Fumarate13$3,091
Albuterol Sulfate HfaAlbuterol Sulfate19$539
Azithromycin24$408
Prednisone12$35

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$209$27,81747 claims
AstraZenecaSymbicort$67$3,09113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 102 pulmonary disease providers in Arkansas.

Other pulmonary disease in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →